Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7669-7673

  Zhang, Ke ^a   Jiang, Li ^a   He, Rong ^a   Li, Bao Liang ^a   Jia, Zhe ^a   Huang, Rong Hai ^a   Mu, Yi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; CYP2W1; Hepatocellular carcinoma; Prognosis

Indexed keywords

CYP2W1 PROTEIN, HUMAN; CYTOCHROME P450; MESSENGER RNA;

ADULT; AGED; CHEMISTRY; FEMALE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER;

EID: 84922395109     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2023-9     Document Type: Article

References (14)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62:394–9. doi:10.3322/caac.21161.
3. Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, et al. Ramón y Cajal S, Johansson I, Ingelman-Sundberg M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006;341:451–8.
4. Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M, et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer—a pilot study. Eur J Cancer. 2009;45:705–12. doi:10.1016/j.ejca.2008.11.031.
5. Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res. 2012;32:3869–74.
6. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M. Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics. 2007;8:1315–25. doi:10.2217/14622416.8.10.1315.
7. Du L, Hoffman SM, Keeney DS. Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol. 2004;195:278–87.
8. Du L, Neis MM, Ladd PA, Lanza DL, Yost GS, Keeney DS. Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol Appl Pharmacol. 2006;213:135–44.
9. Du L, Neis MM, Ladd PA, Keeney DS. Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006;319:1162–71. doi:10.1124/jpet.106.111724.
10. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–107. doi:10.1038/sj.onc.1206557.
11. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16. doi:10.1053/j.gastro.2004.09.011.
12. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.
13. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141:196–202. doi:10.1016/j.surg.2006.06.033.
14. Zhou J, Tang ZY, Wu ZQ, Zhou XD, Ma ZC, Tan CJ, et al. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterol. 2006;53:275–80.